ABIOMED INC Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2022 12 months to Mar 31, 2022	FY2021 12 months to Mar 31, 2021	FY2020 12 months to Mar 31, 2020	FY2019 12 months to Mar 31, 2019	FY2018 12 months to Mar 31, 2018
Net income
Operating activities:
Net income
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
Acquired in-process research & development
Bad debt expense (recoveries)
Stock-based compensation expense
Write-down of inventory and other
Accretion on marketable securities
Change in fair value of investments
Excess tax benefit from stock-based awards
Deferred tax provision
Change in fair value of contingent consideration
Gain on previously held interest in preCARDIA
Other non-cash operating activities
Changes in assets and liabilities:
Accounts receivable, net
Inventories, net
Prepaid expenses and other assets
Accounts payable
Accrued expenses and other liabilities
Deferred revenue

Net cash provided by operating activities
Deferred revenue
Net cash provided by operating activities
Investing activities:
Purchases of marketable securities
Proceeds from the sale and maturity of marketable securities
Payments for acquisition
Precardia
Breethe
Total payments for acquisition
Purchases of other investments and intangible assets
Proceeds from sale of Shockwave Medical Investment
Proceeds from sale of Shockwave Medical securities
Purchase of other investment
Purchases of property and equipment
Net cash used for investing activities
Financing activities:
Proceeds from the exercise of stock options
Taxes paid related to net share settlement upon vesting of stock awards
Payment of Breethe contingent consideration at acquisition date fair value
Repurchase of common stock
Proceeds from the issuance of stock under employee stock purchase plan
Principal payments on capital lease obligation
Net cash (used for) provided by financing activities
Net cash used for financing activities

Effect of exchange rate changes on cash and cash equivalents
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure of cash flow information:
Cash paid for income taxes
Cash paid for interest on capital lease obligation

Supplemental disclosure of non-cash investing and financing activities:
Contingent consideration related to the acquisition of Breethe
Property and equipment in accounts payable and accrued expenses
Right-of-use assets obtained in exchange for lease liabilities

Comments